The Trump administration has intensified restrictions on foreign researchers and students in the U.S., unveiling two significant policy changes within 48 hours. On Wednesday, the Department of Homeland Security proposed imposing a $70,000 fee for the Optional Practical Training program, which foreign students frequently use to gain professional experience. The following day, the Labor Department launched an investigation into nine universities—including Harvard, Stanford, and Yale—over alleged visa fraud involving postdoctoral researchers.
These actions follow ongoing court battles over stricter immigration policies. The DHS is also fighting in court to impose a four-year cap on stays in the U.S. by graduate students and postdocs. while seeking to reinstate a $100,000 fee for H-2B visas, which skilled workers in sectors like biotechnology rely on. None of these measures have taken effect, but experts warn the uncertainty is already discouraging potential applicants.
Data from the Association of American Universities shows that while domestic Ph.D. applications rose by 3% this year, international applications dropped by 21%. The decline indicates that even before new rules are finalized, the perception of heightened barriers is deterring top global talent from applying.
Elizabeth Goss, an immigration attorney based in Boston, called the moves “an incredible series of self-owns.” She added that the government knows these policies won’t survive legal challenges but aims to send a message: “Don’t come here.”
International researchers have long been essential to American biomedical innovation, addressing critical workforce shortages. Current policies threaten that advantage. Unlike other nations, the U.S. has historically attracted global talent through temporary visas, institutional sponsorships, and flexible work authorization. The administration’s approach, high fees, visa investigations, and legal disputes, shifts the financial and administrative burden onto students and universities without offering viable alternatives.
U.S. risks losing global research dominance
This is not the first time immigration policies have reshaped academic recruitment. In the 1990s, stricter visa rules led to a decline in foreign students, though later reforms reversed the trend. Today, the consequences could be more severe: with China and Europe heavily investing in their own research infrastructure, the U.S. risks losing its competitive edge if it enforces these measures aggressively. The question remains whether these actions will permanently deter applicants or serve as a negotiating tactic to pressure universities and employers into concessions.
DEA reverses course on kratom derivatives
A separate development on Friday involved the Drug Enforcement Administration adjusting its proposed classification of two kratom derivatives. Initially, the DEA had planned to list 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI), even in trace amounts, as Schedule I substances, the strictest category for drugs with no accepted medical use. After advocacy groups intervened, the agency modified its stance, focusing instead on concentration thresholds rather than outright bans.
The American Kratom Association, representing supporters of natural kratom products, praised the change, arguing the original rule could have criminalized items containing only trace amounts of MGPI. Critics, including some drug policy experts and lawmakers, continue to push for broader restrictions on all kratom products, including natural forms. The scheduling process remains unresolved, leaving manufacturers and consumers in a state of uncertainty.
Products containing 7-OH or MGPI must now comply with concentration limits-no more than 0.2% of MGPI and 0.5% of 7-OH-to avoid Schedule I classification. This change applies only to synthetic or semi-synthetic derivatives, leaving natural kratom leaf products temporarily exempt. However, the DEA has not ruled out future restrictions on natural forms, particularly if research links them to health risks or misuse.
Pharma incentives skew doctor prescribing habits
A Cochrane review released earlier this month found that even small incentives, such as free meals, significantly alter prescribing habits among doctors. The study analyzed data from multiple trials, showing that physicians who received gifts from pharmaceutical companies were 30% more likely to prescribe those companies’ medications, even when equally effective alternatives were available. The effect increased with exposure: doctors who attended multiple sponsored events prescribed the promoted drugs up to 50% more frequently than peers who received no incentives.
The financial impact is substantial. Pharmaceutical companies spent $250 million on meals alone in 2022, according to industry reports, with heavy investment in specialty fields like oncology and psychiatry. The review noted that the influence extended beyond brand preference, doctors often prescribed higher doses or off-label uses of the promoted drugs, increasing patient risks and healthcare costs. While the study did not examine cash payments, prior research has shown these further amplify the effect, particularly in fields with high diagnostic uncertainty.
The Labor Department’s investigation into Harvard, Stanford, and the seven other targeted universities will proceed independently, with preliminary findings expected within 90 days. While universities have not issued public statements on the allegations, some campuses have already begun internal reviews to identify discrepancies in postdoctoral hiring records.
